LabCorp (LH) announced the availability of a newly-approved companion diagnostic by the U.S. Food and Drug Administration, the therascreen FGFR mutation assay by RGQ RT-PCR, which is now available for ordering from LabCorp and its Integrated Oncology specialty laboratory. QIAGEN (QGEN) developed the assay, which is used to assess the eligibility of patients with urothelial cancer for treatment with the newly approved FGFR kinase inhibitor, BALVERSA.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.